0
0

Sections

Excerpt

Your session has timed out. Please sign back in to continue.
Sign In Your Session has timed out. Please sign back in to continue.
Sign In to Access Full Content
 
Username
Password
Sign in via Athens (What is this?)
Athens is a service for single sign-on which enables access to all of an institution's subscriptions on- or off-site.
Not a subscriber?

Subscribe Now/Learn More

PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing PsychiatryOnline@psych.org or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

FIGURE 26–1. Targeting stress hormone abnormalities as putative treatment options.Activation of the hypothalamic-pituitary-adrenal (HPA) system results in elevation of corticotropin-releasing hormone (CRH), vasopressin, and cortisol, which produce several signs and symptoms of depression and anxiety. Blocking the actions of these neuropeptides at the receptor level provides a new lead for antidepressant and anxiolytic drug discovery.  = increased.

FIGURE 26–2. Effects of a selective CRH1 receptor antagonist on number of entries into open arms of elevated plus-maze.Mice selectively bred for high anxiety-like behavior (HAB) assessed on the elevated plus-maze show increased CRH expression in the PVN (not shown). When HAB mice are treated with a selective CRH1 receptor antagonist, their behavior normalizes and becomes indistinguishable from that of mice with normal anxiety-like behavior (NAB). Hatched bars indicate pretreatment with the CRH1 receptor antagonist DMP-696. CRH = corticotropin-releasing hormone; CRH1 = corticotropin-releasing hormone 1 receptor; CRH2 = corticotropin-releasing hormone 2 receptor; PVN = paraventricular nucleus of the hypothalamus.Source. M. Bunck (Max Planck Institute of Psychiatry, Munich), personal communication, August 2006.

FIGURE 26–3. Results from an open-label proof-of-concept study suggest the potential usefulness of a CRH1 receptor antagonist in severely depressed patients.Two patient samples (n = 10 each) with severe major depression were treated with R 121919, a selective high-affinity CRH1 receptor antagonist. Two different dosage escalation panels with weekly increases from 5–20 mg to 40 mg (black lines) and from 40–60 mg to 80 mg (green lines) were administered, resulting in significantly decreased severity scores on both depression (Hamilton Rating Scale for Depression [Ham-D]) and anxiety (Hamilton Anxiety Scale [Ham-A]) scales. Note that after cessation of active treatment, clinical worsening of depressive and anxiety symptoms was observed. CRH = corticotropin-releasing hormone 1 receptor.Source. Adapted from Zobel et al. 2000.

FIGURE 26–4. A CRH1 receptor antagonist attenuates stress-elicited hormone response.When challenged with a psychosocial stressor, healthy subjects pretreated with the CRH1 receptor antagonist NBI-34041 showed lower secretion of ACTH and cortisol than did untreated subjects. ACTH = adrenocorticotropic hormone; CRH1 = corticotropin-releasing hormone 1 receptor; TSST = Trier Social Stress Test.Source. Adapted from Ising et al. 2007.
Table Reference Number
TABLE 26–1. Expression of CRH and CRH receptors in the rodent central nervous system

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Related Content
Articles
Books
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 3.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 4.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 6.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 8.  >
The American Psychiatric Publishing Textbook of Psychiatry, 5th Edition > Chapter 4.  >
Psychiatric News
 
  • Print
  • PDF
  • E-mail
  • Chapter Alerts
  • Get Citation